Program
Gemcitabine
Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.
Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 681 open or running | phase 3since Nov 6, 2000 | Nov 6, 2000 | May 2027phase 2 · NCT05999994 |
| Hoffmann-La Roche | 181 open or running | phase 4since Mar 19, 2008 | Apr 17, 2007 | Mar 22, 2027phase 1 · NCT06624085 |
| Pfizerits history only | 50 open or running | phase 3since Jan 21, 2000 | Jan 21, 2000 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 2since May 23, 2003 | May 23, 2003 | none ahead |
| Amgenits history only | 30 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 1since Apr 9, 2002 | Apr 9, 2002 | none ahead |
| NovoCureits history only | 20 open or running | phase 2since Oct 23, 2013 | Oct 23, 2013 | none ahead |
| Pierre Fabreits history only | 20 open or running | phase 2since Apr 16, 2012 | Apr 16, 2012 | none ahead |
| Sarah Cannon Research Instituteits history only | 20 open or running | phase 2since Apr 4, 2008 | Apr 4, 2008 | none ahead |
| Theriva Biologics SLits history only | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| BeBetter Medits history only | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Betta Pharmaceuticalsits history only | 10 open or running | phase 4since Jul 16, 2014 | Jul 16, 2014 | none ahead |
| Coherus Oncologyits history only | 11 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Eisaiits history only | 10 open or running | phase 2since May 17, 2010 | May 17, 2010 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | no phasesince Sep 20, 2024 | Sep 20, 2024 | none ahead |
| Meyer Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novaceaits history only | 10 open or running | phase 2since Sep 26, 2007 | Sep 26, 2007 | none ahead |
| Otsukaits history only | 10 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Pharmacosmosits history only | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| Pharmatech Oncologyits history only | 10 open or running | phase 2since Dec 7, 2001 | Dec 7, 2001 | none ahead |
| Relmada Therapeuticsits history only | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| RenovoRxits history only | 10 open or running | phase 1since Sep 8, 2014 | Sep 8, 2014 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| Smartwise Sweden ABits history only | 11 open or running | phase 2since Apr 5, 2026 | Apr 5, 2026 | Dec 2027phase 2 · NCT07575191 |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| SynerGene Therapeuticsits history only | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Apr 17, 2007.
- Feb 9, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerNCT01077713 · 86 enrolled · Italy
- Aug 19, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerNCT01185847 · 90 enrolled · Belgium, France, Germany and more
- Sep 6, 2010Phase 2 study in Breast NeoplasmsNCT01201265 · 40 enrolled · India
- May 23, 2011Phase 1 study in Solid TumorNCT01359696 · 40 enrolled · United States, France
- Mar 23, 2012Phase 1 study in LymphomaNCT01564251 · 104 enrolled · United States, France
- Sep 11, 2012Phase 3 study in Ovarian NeoplasmsNCT01684878 · 208 enrolled · Austria, Belgium, Denmark and more
- Dec 5, 2013Phase 2 study in Urologic NeoplasmsNCT02006667 · 13 enrolled · Germany
- Sep 30, 2015Phase 2 study in Pancreatic NeoplasmsNCT02565641 · 63 enrolled · Korea, Republic of
- Jun 17, 2016Phase 3 study in Carcinoma, Transitional CellNCT02807636 · 1,213 enrolled · United States, Australia, Belgium and more
- Jun 9, 2017Phase 2 study in Pancreatic AdenocarcinomaNCT03193190 · 341 enrolled · United States, Germany, Japan and more
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03337698 · 314 enrolled · United States, Australia, France and more
- Dec 22, 2017Phase 2 study in Uterine Cervical NeoplasmsNCT03386721 · 256 enrolled · United States, Belgium, France and more
- Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellNCT03869190 · 272 enrolled · United States, France, Greece and more
- Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico
Ahead
- Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085
TargetBeta
“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Hydroxyurearule | Norgine | phase 4 | 15 |
Studies
All 18 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06624085Lymphoma · United States, Puerto Rico | 1 | Active, not recruiting | Mar 22, 2027 | 50 |
| NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more | 2 | Terminated | Oct 8, 2025 | 272 |
| NCT03386721Uterine Cervical Neoplasms · United States, Belgium, France and more | 2 | Terminated | Dec 30, 2021 | 256 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Oct 14, 2025 | 314 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Feb 27, 2025 | 341 |
| NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Aug 31, 2022 | 1,213 |
| NCT02565641Pancreatic Neoplasms · Korea, Republic of | 2 | Completed | Sep 2006 | 63 |
| NCT02006667Urologic Neoplasms · Germany | 2 | Completed | Jan 2010 | 13 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Jan 30, 2015 | 208 |
| NCT01564251Lymphoma · United States, France | 1 | Completed | Jan 11, 2018 | 104 |
| NCT01359696Solid Tumor · United States, France | 1 | Completed | May 29, 2014 | 40 |
| NCT01201265Breast Neoplasms · India | 2 | Completed | Apr 2015 | 40 |
| NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more | 2 | Completed | Sep 2012 | 90 |
| NCT01077713Non-Squamous Non-Small Cell Lung Cancer · Italy | 2 | Completed | Jul 2014 | 86 |
| NCT00846027Breast Neoplasms · Spain | 2 | Completed | Dec 2011 | 90 |
| NCT00701558Non-small Cell Lung Cancer Metastatic · Romania | 2 | Completed | Oct 2010 | 20 |
| NCT00642733Pancreatic Neoplasms · Mexico | 4 | Terminated | Apr 2009 | 6 |
| NCT00461708Pancreatic Neoplasms · Spain | 2 | Completed | Nov 2010 | 153 |
How it is read
Names in the registry
- “Gemcitabine”, 113 entries
- “gemcitabine”, 52 entries
- “gemcitabine hydrochloride”, 17 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “EndoTAG-1 and Gemcitabine”, 3 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 53 studies
- Carcinoma, Non-Small-Cell Lung, 42 studies
- Breast Neoplasms, 24 studies
- Neoplasms, 10 studies
- Biliary Tract Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.